Engineering Cationic Liposome

Podesta, Jennifer E.; Kostarelos, Kostas

doi:10.1016/s0076-6879(09)64017-9

Cited by 37 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The simplest method is to mix preformed cationic liposomes with a siRNA solution at a desired ratio to form lipoplexes [32]. These siRNA-lipid complexes do not face the electrostatic barrier when entering the cells, and are easily endocytosed by the plasma membrane.…”

Section: Liposomes and Lipid Nanoparticles For Sirna Deliverymentioning

confidence: 99%

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy

Babu

Muralidharan

Amreddy

et al. 2016

IEEE Trans.on Nanobioscience

View full text Add to dashboard Cite

Gene silencing through RNA interference (RNAi) has emerged as a potential strategy in manipulating cancer causing genes by complementary base-pairing mechanism. Small interfering RNA (siRNA) is an important RNAi tool that has found significant application in cancer therapy. However due to lack of stability, poor cellular uptake and high probability of loss-of-function due to degradation, siRNA therapeutic strategies seek safe and efficient delivery vehicles for in vivo applications. The current review discusses various nanoparticle systems currently used for siRNA delivery for cancer therapy, with emphasis on liposome based gene delivery systems. The discussion also includes various methods availed to improve nanoparticle based-siRNA delivery with target specificity and superior efficiency. Further this review describes challenges and perspectives on the development of safe and efficient nanoparticle based-siRNA-delivery systems for cancer therapy.

show abstract

Section: Liposomes and Lipid Nanoparticles For Sirna Deliverymentioning

confidence: 99%

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy

Babu

Muralidharan

Amreddy

et al. 2016

IEEE Trans.on Nanobioscience

View full text Add to dashboard Cite

show abstract

“…Any RNAs less than 50 kDa are filtered through the kidney and excreted so local delivery of the modified RNAs is preferred. A possible solution to this challenge is to use PEGylated liposomes that are lipid vesicles within which nucleic acids can be encapsulated to avoid being filtered by the kidneys (Podesta and Kostarelos, 2009; McCaskill et al, 2013). To improve the mode of RNA delivery, one of the formulations used was lipid nanoparticle (Shi et al, 2011; Asai and Oku, 2014).…”

Section: Mirna Therapeutics - An Insight On the Future For Sarcomasmentioning

confidence: 99%

MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

Varshney

Subramanian

2015

Front. Mol. Biosci.

View full text Add to dashboard Cite

Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

show abstract

“…Neutral nanoliposomes are not toxic to normal cells such as fibroblasts or hematopoietic cells, making them potentially clinically useful [18, 44]. Liposomes developed using neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) deliver siRNAs more effectively into tumor cells than cationic liposomes (DOTAP) or using naked siRNA [45].…”

Section: 0 Nanotechnology Based Drug Delivery Systemsmentioning

confidence: 99%

“…In addition, since phospholipids used in the preparation of liposomes, such as phosphatidylcholine and phosphatidylethanolamine, also present in natural cell membranes, liposomes are the ideal candidates for preparing biocompatible and biodegradable carriers [18]. Liposomes can enhance half-life of various therapeutic agents [49].…”

Section: 0 Nanotechnology Based Drug Delivery Systemsmentioning

confidence: 99%